The efficacy, acceptability, and tolerability of tioconazole solution (1%) in a pump spray were evaluated in an open-label trial in 26 patients with dermatophytosis, superficial candidiasis, and tinea versicolor. Medication was applied twice daily for 30 consecutive days. Eighteen patients had dermatophyte lesions: four patients had tinea pedis interdigitalis (one of these also had tinea cruris), and 14 patients had tinea corporis. Of these, four patients did not respond to treatment and were considered therapeutic failures and ten were carriers and remained so one month after therapy. Five patients were clinically and mycologically cured at the end of therapy and did not relapse one month after therapy. All of the eight remaining patients were clinically and mycologically cured at the end of treatment and one month later: these included seven patients with tinea versicolor and one with anal candidiasis.